Racial/ethnic disparities in treatment with bone-modifying agents among newly diagnosed multiple myeloma patients

According to data from a retrospective cohort study—presented during the American Association for Cancer Research 2022 Annual Meeting—of patients with newly diagnosed multiple myeloma, higher rates of bone-modifying agent initiation were observed among Asian (55%), White (51%), and Latinx (50%) patients compared to Black patients (44%; P=0.023). Future research is needed to determine whether these disparities affect overall and progression-free survival in this patient population.